The University of Chicago Header Logo

Connection

David Rubin to Middle Aged

Back to Details
This is a "connection" page, showing publications David Rubin has written about Middle Aged.
David Rubin
Connection Strength
3.574
Middle Aged
  1. Deployment of an Artificial Intelligence Histology Tool to Aid Qualitative Assessment of Histopathology Using the Nancy Histopathology Index in Ulcerative Colitis. Inflamm Bowel Dis. 2025 Jun 13; 31(6):1630-1636.
    View in: PubMed
    Score: 0.061
  2. Mirikizumab in the Treatment of Ulcerative Colitis: Initial Real-World Data in a Population from a Large Tertiary Center. Dig Dis Sci. 2025 May; 70(5):1864-1872.
    View in: PubMed
    Score: 0.060
  3. Mirikizumab Sustained Impact on Fatigue in Patients with Moderately to Severely Active Crohn's Disease in the Phase 2 AMAG Study. Inflamm Bowel Dis. 2025 Feb 06; 31(2):432-441.
    View in: PubMed
    Score: 0.060
  4. Endoscopic Normalization and Transition of J-Pouch Phenotypes Over Time in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2025 01 06; 31(1):63-71.
    View in: PubMed
    Score: 0.059
  5. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies. Lancet. 2025 01 04; 405(10472):33-49.
    View in: PubMed
    Score: 0.059
  6. Efficacy and Safety of GLP-1 Agonists on Metabolic Parameters in Non-diabetic Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2024 Dec; 69(12):4437-4445.
    View in: PubMed
    Score: 0.059
  7. Dose escalation of biologics in biologic-naive patients with Crohn's disease: Outcomes from the ODESSA-CD study. J Manag Care Spec Pharm. 2024 Nov; 30(11):1276-1287.
    View in: PubMed
    Score: 0.059
  8. Real-World Persistence of Successive Biologics in Patients With Inflammatory Bowel Disease: Findings From ROTARY. Inflamm Bowel Dis. 2024 10 03; 30(10):1776-1787.
    View in: PubMed
    Score: 0.058
  9. Impact of a health-system specialty pharmacy on time to upadacitinib initiation. Am J Health Syst Pharm. 2024 Sep 23; 81(19):e594-e600.
    View in: PubMed
    Score: 0.058
  10. Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease receiving different sequences of first- and second-line biologic treatments: findings from ROTARY. BMC Gastroenterol. 2024 Sep 17; 24(1):314.
    View in: PubMed
    Score: 0.058
  11. The Communicating Needs and Features of IBD Experiences (CONFIDE) Study: US and European Patient and Health Care Professional Perceptions of the Experience and Impact of Symptoms of Moderate-to-Severe Ulcerative Colitis. Inflamm Bowel Dis. 2024 06 03; 30(6):939-949.
    View in: PubMed
    Score: 0.057
  12. Utility of the Endoscopic Healing Index in Identifying Active Inflammation in Patients with Crohn's Disease: Real World Data from a Tertiary Center. Dig Dis Sci. 2024 Aug; 69(8):2955-2960.
    View in: PubMed
    Score: 0.057
  13. Ozanimod-exposed Patients with Ulcerative Colitis Undergoing Total Colectomy Exhibit Unique Lymph Node Histological Changes. J Crohns Colitis. 2024 Apr 23; 18(4):638-641.
    View in: PubMed
    Score: 0.057
  14. Risankizumab Effectiveness and Safety in Crohn's Disease: Real-world Data From a Large Tertiary Center. Clin Gastroenterol Hepatol. 2024 Jun; 22(6):1336-1338.e2.
    View in: PubMed
    Score: 0.055
  15. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. Lancet Gastroenterol Hepatol. 2022 01; 7(1):17-27.
    View in: PubMed
    Score: 0.048
  16. Ulcerative Colitis Patients Have Reduced Rectal Compliance Compared With Non-Inflammatory Bowel Disease Controls. Gastroenterology. 2022 01; 162(1):331-333.e1.
    View in: PubMed
    Score: 0.047
  17. SARS-CoV-2 Infection in Public School District Employees Following a District-Wide Vaccination Program - Philadelphia County, Pennsylvania, March 21-April 23, 2021. MMWR Morb Mortal Wkly Rep. 2021 Jul 30; 70(30):1040-1043.
    View in: PubMed
    Score: 0.047
  18. Quantitative Variable Assessment of Patellar Instability: An MRI-Based Study. AJR Am J Roentgenol. 2020 11; 215(5):1163-1170.
    View in: PubMed
    Score: 0.044
  19. Poor Sleep Quality in Crohn's Disease Is Associated With Disease Activity and Risk for Hospitalization or Surgery. Inflamm Bowel Dis. 2020 07 17; 26(8):1251-1259.
    View in: PubMed
    Score: 0.044
  20. Long-Duration Oral Vancomycin to Treat Clostridioides difficile in Patients With Inflammatory Bowel Disease Is Associated With a Low Rate of Recurrence. Am J Gastroenterol. 2019 12; 114(12):1904-1908.
    View in: PubMed
    Score: 0.042
  21. Low-Dose Metronidazole is Associated With a Decreased Rate of Endoscopic Recurrence of Crohn's Disease After Ileal Resection: A Retrospective Cohort Study. J Crohns Colitis. 2019 Sep 19; 13(9):1158-1162.
    View in: PubMed
    Score: 0.041
  22. Abnormal Pouchogram Predicts Pouch Failure Even in Asymptomatic Patients. Dis Colon Rectum. 2019 04; 62(4):463-469.
    View in: PubMed
    Score: 0.040
  23. Real-World Experience with Tofacitinib in IBD at a Tertiary Center. Dig Dis Sci. 2019 07; 64(7):1945-1951.
    View in: PubMed
    Score: 0.039
  24. Emerging Therapies for Inflammatory Bowel Disease. Adv Ther. 2018 11; 35(11):1746-1762.
    View in: PubMed
    Score: 0.039
  25. Higher Thioguanine Nucleotide Metabolite Levels are Associated With Better Long-term Outcomes in Patients With Inflammatory Bowel Diseases. J Clin Gastroenterol. 2018 07; 52(6):537-544.
    View in: PubMed
    Score: 0.038
  26. Efficacy and Follow-up of Segmental or Subtotal Colectomy in Patients With Colitis-Associated Neoplasia. Clin Gastroenterol Hepatol. 2019 01; 17(1):205-206.
    View in: PubMed
    Score: 0.037
  27. Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. Inflamm Bowel Dis. 2018 03 19; 24(4):849-860.
    View in: PubMed
    Score: 0.037
  28. Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study. Dig Dis Sci. 2018 04; 63(4):1016-1024.
    View in: PubMed
    Score: 0.037
  29. Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. Aliment Pharmacol Ther. 2018 Mar; 47(6):753-762.
    View in: PubMed
    Score: 0.037
  30. Assessment of peri-polyp biopsy specimens of flat mucosa in patients with inflammatory bowel disease. Gastrointest Endosc. 2018 May; 87(5):1304-1309.
    View in: PubMed
    Score: 0.037
  31. Effects of non-medical switching on outcomes among patients prescribed tumor necrosis factor inhibitors. Curr Med Res Opin. 2017 11; 33(11):1945-1953.
    View in: PubMed
    Score: 0.036
  32. Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. J Crohns Colitis. 2017 Jul 01; 11(7):785-791.
    View in: PubMed
    Score: 0.035
  33. Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United States. PLoS One. 2017; 12(4):e0175099.
    View in: PubMed
    Score: 0.035
  34. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis. J Manag Care Spec Pharm. 2017 Aug; 23(8):859-867.
    View in: PubMed
    Score: 0.035
  35. Detection of adalimumab and antibodies to adalimumab using a homogeneous mobility shift assay. Curr Med Res Opin. 2017 May; 33(5):837-843.
    View in: PubMed
    Score: 0.034
  36. The Crohn's and Colitis Foundation of America Survey of Inflammatory Bowel Disease Patient Health Care Access. Inflamm Bowel Dis. 2017 02; 23(2):224-232.
    View in: PubMed
    Score: 0.034
  37. Assessment of corticosteroid-related quality of care measures for ulcerative colitis and Crohn's disease in the United States: a claims data analysis. Curr Med Res Opin. 2017 03; 33(3):529-536.
    View in: PubMed
    Score: 0.034
  38. Zinc Deficiency is Associated with Poor Clinical Outcomes in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 01; 23(1):152-157.
    View in: PubMed
    Score: 0.034
  39. Many Inflammatory Bowel Disease Patients Are Not Immune to Measles or Pertussis. Dig Dis Sci. 2016 10; 61(10):2972-2976.
    View in: PubMed
    Score: 0.033
  40. Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial. J Crohns Colitis. 2016 Aug; 10(8):925-33.
    View in: PubMed
    Score: 0.032
  41. Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis. Dig Dis Sci. 2015 Nov; 60(11):3408-17.
    View in: PubMed
    Score: 0.031
  42. U.S. Patients with Ulcerative Colitis Do Not Have a Decreased Risk of Diverticulosis. Inflamm Bowel Dis. 2015 Sep; 21(9):2154-7.
    View in: PubMed
    Score: 0.031
  43. Penetrating Disease, Narcotic Use, and Loop Ostomy Are Associated with Ostomy and IBD-related Complications After Ostomy Surgery in Crohn's Disease Patients. J Gastrointest Surg. 2015 Oct; 19(10):1852-61.
    View in: PubMed
    Score: 0.031
  44. Hematochezia and a Mesenteric Mass. Gastroenterology. 2015 Jul; 149(1):e12-3.
    View in: PubMed
    Score: 0.030
  45. Optimal doses of methotrexate combined with anti-TNF therapy to maintain clinical remission in inflammatory bowel disease. J Crohns Colitis. 2015 Apr; 9(4):312-7.
    View in: PubMed
    Score: 0.030
  46. Patchy colitis and interstitial lung disease. Gastroenterology. 2015 Jan; 148(1):26-7.
    View in: PubMed
    Score: 0.029
  47. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease. Aliment Pharmacol Ther. 2014 May; 39(10):1143-55.
    View in: PubMed
    Score: 0.028
  48. Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn's disease. Inflamm Bowel Dis. 2013 Nov; 19(12):2577-83.
    View in: PubMed
    Score: 0.027
  49. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol. 2013 Dec; 11(12):1601-8.e1-4.
    View in: PubMed
    Score: 0.027
  50. Patient perceptions of fecal microbiota transplantation for ulcerative colitis. Inflamm Bowel Dis. 2013 Jun; 19(7):1506-13.
    View in: PubMed
    Score: 0.027
  51. Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center. Inflamm Bowel Dis. 2013 Mar; 19(3):621-6.
    View in: PubMed
    Score: 0.026
  52. Long-term treatment of patients with a history of ulcerative colitis who develop gastritis and pan-enteritis after colectomy. J Clin Gastroenterol. 2013 Jan; 47(1):52-7.
    View in: PubMed
    Score: 0.026
  53. Response to biologic therapy in Crohn's disease is improved with early treatment: an analysis of health claims data. Inflamm Bowel Dis. 2012 Dec; 18(12):2225-31.
    View in: PubMed
    Score: 0.024
  54. Assessment of variables associated with smoking cessation in Crohn's disease. Dig Dis Sci. 2012 Apr; 57(4):1026-32.
    View in: PubMed
    Score: 0.024
  55. Total abdominal colectomy for refractory ulcerative colitis. Surgical treatment in evolution. J Gastrointest Surg. 2011 Nov; 15(11):1909-16.
    View in: PubMed
    Score: 0.024
  56. Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial. Inflamm Bowel Dis. 2012 May; 18(5):818-25.
    View in: PubMed
    Score: 0.024
  57. Fecal bacteriotherapy for ulcerative colitis: patients are ready, are we? Inflamm Bowel Dis. 2012 Apr; 18(4):676-84.
    View in: PubMed
    Score: 0.023
  58. Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center. Inflamm Bowel Dis. 2012 Jan; 18(1):10-6.
    View in: PubMed
    Score: 0.023
  59. Active Crohn's disease in the small bowel: evaluation by diffusion weighted imaging and quantitative dynamic contrast enhanced MR imaging. J Magn Reson Imaging. 2011 Mar; 33(3):615-24.
    View in: PubMed
    Score: 0.023
  60. Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysis. Aliment Pharmacol Ther. 2011 Mar; 33(6):672-8.
    View in: PubMed
    Score: 0.023
  61. Outcome after surveillance of low-grade and indefinite dysplasia in patients with ulcerative colitis. Inflamm Bowel Dis. 2010 Aug; 16(8):1352-6.
    View in: PubMed
    Score: 0.022
  62. Do colorectal cancer patients understand that their family is at risk? Dig Dis Sci. 2009 Nov; 54(11):2473-83.
    View in: PubMed
    Score: 0.021
  63. The impact of ulcerative colitis on patients' lives compared to other chronic diseases: a patient survey. Dig Dis Sci. 2010 Apr; 55(4):1044-52.
    View in: PubMed
    Score: 0.020
  64. Genetic testing for inflammatory bowel disease: focus group analysis of patients and family members. Genet Test Mol Biomarkers. 2009 Aug; 13(4):495-503.
    View in: PubMed
    Score: 0.020
  65. Association of colorectal cancer and prostate cancer and impact of radiation therapy. Cancer Epidemiol Biomarkers Prev. 2009 Jul; 18(7):1979-85.
    View in: PubMed
    Score: 0.020
  66. Positron emission tomography (PET) used to image subclinical inflammation associated with ulcerative colitis (UC) in remission. Inflamm Bowel Dis. 2009 May; 15(5):750-5.
    View in: PubMed
    Score: 0.020
  67. Impact of ulcerative colitis from patients' and physicians' perspectives: Results from the UC: NORMAL survey. Inflamm Bowel Dis. 2009 Apr; 15(4):581-8.
    View in: PubMed
    Score: 0.020
  68. Identification of patients at increased risk for colorectal cancer in an open access endoscopy center. J Clin Gastroenterol. 2008 Oct; 42(9):1025-31.
    View in: PubMed
    Score: 0.019
  69. Association between colorectal cancer and urologic cancers. Arch Intern Med. 2008 May 12; 168(9):1003-9.
    View in: PubMed
    Score: 0.019
  70. p53 mutations are associated with dysplasia and progression of dysplasia in patients with Crohn's disease. Dig Dis Sci. 2008 Feb; 53(2):474-80.
    View in: PubMed
    Score: 0.018
  71. What is the most effective way to communicate results after endoscopy? Gastrointest Endosc. 2007 Jul; 66(1):108-12.
    View in: PubMed
    Score: 0.018
  72. Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Gastrointest Endosc. 2007 Jun; 65(7):998-1004.
    View in: PubMed
    Score: 0.017
  73. Surveillance of dysplasia in inflammatory bowel disease: The gastroenterologist-pathologist partnership. Clin Gastroenterol Hepatol. 2006 Nov; 4(11):1309-13.
    View in: PubMed
    Score: 0.017
  74. Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol. 2006 Nov; 4(11):1346-50.
    View in: PubMed
    Score: 0.017
  75. Comparison of routine and unprepped CT colonography augmented by low fiber diet and stool tagging: a pilot study. Abdom Imaging. 2007 Jan-Feb; 32(1):96-104.
    View in: PubMed
    Score: 0.017
  76. Do patients with inflammatory bowel disease want genetic testing? Inflamm Bowel Dis. 2006 Jun; 12(6):497-502.
    View in: PubMed
    Score: 0.016
  77. Health-Related Quality of Life Outcomes With Etrasimod Treatment in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From ELEVATE UC 52 and ELEVATE UC 12. Inflamm Bowel Dis. 2025 Jun 13; 31(6):1583-1594.
    View in: PubMed
    Score: 0.015
  78. Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn's disease and ulcerative colitis. J Crohns Colitis. 2025 Jun 04; 19(6).
    View in: PubMed
    Score: 0.015
  79. Association of bile acid diarrhea with symptoms and disease activity in Crohn's disease: post-hoc clinical trial analysis of serum 7a-hydroxy-4cholestern-3-one, C4, in patients with active Crohn's disease. J Crohns Colitis. 2025 May 08; 19(5).
    View in: PubMed
    Score: 0.015
  80. Global evolution of inflammatory bowel disease across epidemiologic stages. Nature. 2025 Jun; 642(8067):458-466.
    View in: PubMed
    Score: 0.015
  81. The Effect of Etrasimod on Fecal Calprotectin and High-sensitivity C-reactive Protein: Results From the ELEVATE UC Clinical Program. Inflamm Bowel Dis. 2025 Apr 10; 31(4):923-934.
    View in: PubMed
    Score: 0.015
  82. Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis. J Crohns Colitis. 2025 Apr 04; 19(4).
    View in: PubMed
    Score: 0.015
  83. Etrasimod Corticosteroid-Free Efficacy, Impact of Concomitant Corticosteroids on Efficacy and Safety, and Corticosteroid-Sparing Effect in Ulcerative Colitis: Analyses of the ELEVATE UC Clinical Program. J Crohns Colitis. 2025 Mar 05; 19(3).
    View in: PubMed
    Score: 0.015
  84. Continuous Monitoring of CRP, IL-6, and Calprotectin in Inflammatory Bowel Disease Using a Perspiration-Based Wearable Device. Inflamm Bowel Dis. 2025 Mar 03; 31(3):647-654.
    View in: PubMed
    Score: 0.015
  85. Frequency of Spondyloarthritis Symptoms Among US Patients With Inflammatory Bowel Disease: A Cross-Sectional Multi-Center Study. Arthritis Care Res (Hoboken). 2025 Jun; 77(6):777-784.
    View in: PubMed
    Score: 0.015
  86. Multiomic analysis reveals cellular, transcriptomic and epigenetic changes in intestinal pouches of ulcerative colitis patients. Nat Commun. 2025 Jan 21; 16(1):904.
    View in: PubMed
    Score: 0.015
  87. Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies. J Crohns Colitis. 2025 Jan 11; 19(1).
    View in: PubMed
    Score: 0.015
  88. Cardiovascular events observed among patients in the etrasimod clinical programme: an integrated safety analysis of patients with moderately to severely active ulcerative colitis. BMJ Open Gastroenterol. 2025 Jan 08; 12(1).
    View in: PubMed
    Score: 0.015
  89. Tamuzimod in patients with moderately-to-severely active ulcerative colitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trial. Lancet Gastroenterol Hepatol. 2025 03; 10(3):210-221.
    View in: PubMed
    Score: 0.015
  90. Extensive Disease and Exposure to Multiple Biologics Precolectomy Is Associated with Endoscopic Cuffitis Post-Ileal Pouch-Anal Anastomosis in Patients With Ulcerative Colitis. Inflamm Bowel Dis. 2025 01 06; 31(1):72-76.
    View in: PubMed
    Score: 0.015
  91. Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2025 02; 10(2):138-153.
    View in: PubMed
    Score: 0.015
  92. Noninvasive, microbiome-based diagnosis of inflammatory bowel disease. Nat Med. 2024 Dec; 30(12):3555-3567.
    View in: PubMed
    Score: 0.015
  93. Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis. N Engl J Med. 2024 09 26; 391(12):1119-1129.
    View in: PubMed
    Score: 0.015
  94. Impact of Baseline Corticosteroid Use on the Efficacy and Safety of Upadacitinib in Patients with Ulcerative Colitis: A Post Hoc Analysis of the Phase 3 Clinical Trial Programme. J Crohns Colitis. 2024 May 31; 18(5):695-707.
    View in: PubMed
    Score: 0.014
  95. Patient and Health Care Professional Perceptions of the Experience and Impact of Symptoms of Moderate-to-Severe Crohn's Disease in US and Europe: Results from the Cross-Sectional CONFIDE Study. Dig Dis Sci. 2024 Jul; 69(7):2333-2344.
    View in: PubMed
    Score: 0.014
  96. Analysis of Clinical Trial Screen Failures in Inflammatory Bowel Diseases [IBD]: Real World Results from the International Organization for the study of IBD. J Crohns Colitis. 2024 Apr 23; 18(4):548-559.
    View in: PubMed
    Score: 0.014
  97. Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn's Disease Regardless of Prior Biologic Exposure. Clin Gastroenterol Hepatol. 2024 Oct; 22(10):2096-2106.
    View in: PubMed
    Score: 0.014
  98. Long-Term Safety Outcomes of Fecal Microbiota Transplantation: Real-World Data Over 8 Years From the Hong Kong FMT Registry. Clin Gastroenterol Hepatol. 2024 Mar; 22(3):611-620.e12.
    View in: PubMed
    Score: 0.014
  99. Quality of Care Program Reduces Unplanned Health Care Utilization in Patients With Inflammatory Bowel Disease. Am J Gastroenterol. 2021 12 01; 116(12):2410-2418.
    View in: PubMed
    Score: 0.012
  100. Vedolizumab and Anti-Tumour Necrosis Factor a Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study. J Crohns Colitis. 2021 Oct 07; 15(10):1694-1706.
    View in: PubMed
    Score: 0.012
  101. Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium. Lancet Gastroenterol Hepatol. 2021 10; 6(10):826-849.
    View in: PubMed
    Score: 0.012
  102. Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial. J Crohns Colitis. 2021 Jul 05; 15(7):1130-1141.
    View in: PubMed
    Score: 0.012
  103. Fecal Microbiota Transplantation for Recurrent C difficile Infection During the COVID-19 Pandemic: Experience and Recommendations. Mayo Clin Proc. 2021 06; 96(6):1418-1425.
    View in: PubMed
    Score: 0.012
  104. Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visit. J Manag Care Spec Pharm. 2021 Aug; 27(8):1086-1095.
    View in: PubMed
    Score: 0.011
  105. Cardiac Corrected QT Interval Changes Among Patients Treated for COVID-19 Infection During the Early Phase of the Pandemic. JAMA Netw Open. 2021 04 01; 4(4):e216842.
    View in: PubMed
    Score: 0.011
  106. Histologic remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission. Aliment Pharmacol Ther. 2020 12; 52(11-12):1676-1682.
    View in: PubMed
    Score: 0.011
  107. Fecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry. Gastroenterology. 2021 01; 160(1):183-192.e3.
    View in: PubMed
    Score: 0.011
  108. Long-term safety of vedolizumab for inflammatory bowel disease. Aliment Pharmacol Ther. 2020 10; 52(8):1353-1365.
    View in: PubMed
    Score: 0.011
  109. Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis. Gastroenterology. 2020 12; 159(6):2052-2064.
    View in: PubMed
    Score: 0.011
  110. Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2020 06; 51(12):1365-1372.
    View in: PubMed
    Score: 0.011
  111. Impact of Physician Payments on Microvascular Breast Reconstruction: An All-Payer Claim Database Analysis. Plast Reconstr Surg. 2020 Feb; 145(2):333-339.
    View in: PubMed
    Score: 0.011
  112. The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn's & Colitis Foundation. Inflamm Bowel Dis. 2020 01 01; 26(1):1-10.
    View in: PubMed
    Score: 0.010
  113. IBD-associated Colon Cancers Differ in DNA Methylation and Gene Expression Profiles Compared With Sporadic Colon Cancers. J Crohns Colitis. 2019 Jul 25; 13(7):884-893.
    View in: PubMed
    Score: 0.010
  114. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. J Gastroenterol Hepatol. 2019 Dec; 34(12):2090-2095.
    View in: PubMed
    Score: 0.010
  115. Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending. J Manag Care Spec Pharm. 2019 Jul; 25(7):770-779.
    View in: PubMed
    Score: 0.010
  116. Targeted mutational analysis of inflammatory bowel disease-associated colorectal cancers. Hum Pathol. 2019 07; 89:44-50.
    View in: PubMed
    Score: 0.010
  117. Differential risk of disease progression between isolated anastomotic ulcers and mild ileal recurrence after ileocolonic resection in patients with Crohn's disease. Gastrointest Endosc. 2019 08; 90(2):269-275.
    View in: PubMed
    Score: 0.010
  118. Patient-provider communications about pharmacogenomic results increase patient recall of medication changes. Pharmacogenomics J. 2019 12; 19(6):528-537.
    View in: PubMed
    Score: 0.010
  119. The Influence of Physician Payments on the Method of Breast Reconstruction: A National Claims Analysis. Plast Reconstr Surg. 2018 10; 142(4):434e-442e.
    View in: PubMed
    Score: 0.010
  120. A comparison of the risk of postoperative recurrence between African-American and Caucasian patients with Crohn's disease. Aliment Pharmacol Ther. 2018 11; 48(9):933-940.
    View in: PubMed
    Score: 0.010
  121. Utility of video capsule endoscopy for longitudinal monitoring of Crohn's disease activity in the small bowel: a prospective study. Gastrointest Endosc. 2018 12; 88(6):947-955.e2.
    View in: PubMed
    Score: 0.010
  122. Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy. Inflamm Bowel Dis. 2018 05 18; 24(6):1291-1297.
    View in: PubMed
    Score: 0.009
  123. Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2. J Crohns Colitis. 2018 Apr 27; 12(5):621-626.
    View in: PubMed
    Score: 0.009
  124. Prevention of colonic neoplasia with polyethylene glycol: A short term randomized placebo-controlled double-blinded trial. PLoS One. 2018; 13(4):e0193544.
    View in: PubMed
    Score: 0.009
  125. Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis. Dig Dis Sci. 2018 May; 63(5):1294-1301.
    View in: PubMed
    Score: 0.009
  126. The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease. Inflamm Bowel Dis. 2018 02 15; 24(3):502-509.
    View in: PubMed
    Score: 0.009
  127. Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies. J Crohns Colitis. 2018 Jan 24; 12(2):145-156.
    View in: PubMed
    Score: 0.009
  128. Factors associated with readmission to the hospital within 30 days in patients with inflammatory bowel disease. PLoS One. 2017; 12(8):e0182900.
    View in: PubMed
    Score: 0.009
  129. miR-4728-3p Functions as a Tumor Suppressor in Ulcerative Colitis-associated Colorectal Neoplasia Through Regulation of Focal Adhesion Signaling. Inflamm Bowel Dis. 2017 08; 23(8):1328-1337.
    View in: PubMed
    Score: 0.009
  130. Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis Frequently Have Subclinical Inflammation in the Proximal Colon. Clin Gastroenterol Hepatol. 2018 Jan; 16(1):68-74.
    View in: PubMed
    Score: 0.009
  131. Risk of Postoperative Complications Among Inflammatory Bowel Disease Patients Treated Preoperatively With Vedolizumab. Am J Gastroenterol. 2017 Sep; 112(9):1423-1429.
    View in: PubMed
    Score: 0.009
  132. Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing. Clin Pharmacol Ther. 2017 Nov; 102(5):859-869.
    View in: PubMed
    Score: 0.009
  133. miR-193a-3p is a Key Tumor Suppressor in Ulcerative Colitis-Associated Colon Cancer and Promotes Carcinogenesis through Upregulation of IL17RD. Clin Cancer Res. 2017 Sep 01; 23(17):5281-5291.
    View in: PubMed
    Score: 0.009
  134. The Drivers of Discretionary Utilization: Clinical History Versus Physician Supply. Acad Med. 2017 05; 92(5):703-708.
    View in: PubMed
    Score: 0.009
  135. Patient Perceptions of Care as Influenced by a Large Institutional Pharmacogenomic Implementation Program. Clin Pharmacol Ther. 2017 07; 102(1):106-114.
    View in: PubMed
    Score: 0.009
  136. Communication Between Physicians and Patients with Ulcerative Colitis: Reflections and Insights from a Qualitative Study of In-Office Patient-Physician Visits. Inflamm Bowel Dis. 2017 04; 23(4):494-501.
    View in: PubMed
    Score: 0.009
  137. Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial. Aliment Pharmacol Ther. 2017 01; 45(2):264-275.
    View in: PubMed
    Score: 0.008
  138. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. Clin Gastroenterol Hepatol. 2017 02; 15(2):229-239.e5.
    View in: PubMed
    Score: 0.008
  139. Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study. Inflamm Bowel Dis. 2016 08; 22(8):1870-80.
    View in: PubMed
    Score: 0.008
  140. Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies. Inflamm Bowel Dis. 2016 08; 22(8):1881-6.
    View in: PubMed
    Score: 0.008
  141. Serum 25-hydroxyvitamin D concentration is inversely associated with mucosal inflammation in patients with ulcerative colitis. Am J Clin Nutr. 2016 07; 104(1):113-20.
    View in: PubMed
    Score: 0.008
  142. Age of Diagnosis is Associated with Disease Presentation and Therapeutic Complications in Patients with Crohn's Disease. Inflamm Bowel Dis. 2016 May; 22(5):1027-31.
    View in: PubMed
    Score: 0.008
  143. Clostridium Difficile Infection in Ulcerative Colitis: Can Alteration of the Gut-associated Microbiome Contribute to Pouch Failure? Inflamm Bowel Dis. 2016 Apr; 22(4):902-11.
    View in: PubMed
    Score: 0.008
  144. Patients with Ulcerative Colitis Are More Concerned About Complications of Their Disease than Side Effects of Medications. Inflamm Bowel Dis. 2016 Apr; 22(4):940-7.
    View in: PubMed
    Score: 0.008
  145. Surveillance of IBD Using High Definition Colonoscopes Does Not Miss Adenocarcinoma in Patients with Low-grade Dysplasia. Inflamm Bowel Dis. 2016 Mar; 22(3):631-7.
    View in: PubMed
    Score: 0.008
  146. Association between serrated epithelial changes and colorectal dysplasia in inflammatory bowel disease. Gastrointest Endosc. 2016 Jul; 84(1):87-95.e1.
    View in: PubMed
    Score: 0.008
  147. Spectral biomarkers for chemoprevention of colonic neoplasia: a placebo-controlled double-blinded trial with aspirin. Gut. 2017 02; 66(2):285-292.
    View in: PubMed
    Score: 0.008
  148. Health Insurance Paid Costs and Drivers of Costs for Patients With Crohn's Disease in the United States. Am J Gastroenterol. 2016 Jan; 111(1):15-23.
    View in: PubMed
    Score: 0.008
  149. Deep enteroscopy with a conventional colonoscope: initial multicenter study by using a through-the-scope balloon catheter system. Gastrointest Endosc. 2015 Nov; 82(5):855-60.
    View in: PubMed
    Score: 0.008
  150. Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy. Clin Gastroenterol Hepatol. 2015 Nov; 13(11):1919-25.
    View in: PubMed
    Score: 0.008
  151. Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook. Gastroenterology. 2015 Jul; 149(1):223-37.
    View in: PubMed
    Score: 0.008
  152. Incidence and predictors of clinical response, re-induction dose, and maintenance dose escalation with certolizumab pegol in Crohn's disease. Inflamm Bowel Dis. 2014 Oct; 20(10):1722-8.
    View in: PubMed
    Score: 0.007
  153. Clinical presentation and disease course of inflammatory bowel disease differs by race in a large tertiary care hospital. Dig Dis Sci. 2014 Sep; 59(9):2228-35.
    View in: PubMed
    Score: 0.007
  154. Rescue therapy with cyclosporine or infliximab is not associated with an increased risk for postoperative complications in patients hospitalized for severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis. 2014 Jan; 20(1):14-20.
    View in: PubMed
    Score: 0.007
  155. Serum adalimumab concentration and clinical remission in patients with Crohn's disease. Inflamm Bowel Dis. 2013 May; 19(6):1112-22.
    View in: PubMed
    Score: 0.007
  156. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2013 Feb; 19(2):363-9.
    View in: PubMed
    Score: 0.006
  157. Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013 Mar; 37(5):546-54.
    View in: PubMed
    Score: 0.006
  158. Low-dose smoking resumption in ex-smokers with refractory ulcerative colitis. J Crohns Colitis. 2012 Aug; 6(7):756-62.
    View in: PubMed
    Score: 0.006
  159. miR-143 and miR-145 are downregulated in ulcerative colitis: putative regulators of inflammation and protooncogenes. Inflamm Bowel Dis. 2012 Jan; 18(1):94-100.
    View in: PubMed
    Score: 0.006
  160. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut. 2011 Jul; 60(7):937-43.
    View in: PubMed
    Score: 0.006
  161. When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient preferences and physician recommendations. Inflamm Bowel Dis. 2010 Oct; 16(10):1658-62.
    View in: PubMed
    Score: 0.006
  162. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis. 2009 Sep; 15(9):1302-7.
    View in: PubMed
    Score: 0.005
  163. Quantitative analysis of dynamic contrast enhanced MRI for assessment of bowel inflammation in Crohn's disease pilot study. Acad Radiol. 2009 Oct; 16(10):1223-30.
    View in: PubMed
    Score: 0.005
  164. Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. Aliment Pharmacol Ther. 2009 Feb 01; 29(3):247-57.
    View in: PubMed
    Score: 0.005
  165. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol. 2008 Dec; 103(12):3132-41.
    View in: PubMed
    Score: 0.005
  166. Claudin-1 and claudin-2 expression is elevated in inflammatory bowel disease and may contribute to early neoplastic transformation. Lab Invest. 2008 Oct; 88(10):1110-20.
    View in: PubMed
    Score: 0.005
  167. Agile patency system eliminates risk of capsule retention in patients with known intestinal strictures who undergo capsule endoscopy. Gastrointest Endosc. 2008 May; 67(6):902-9.
    View in: PubMed
    Score: 0.005
  168. Analysis of air contrast barium enema, computed tomographic colonography, and colonoscopy: prospective comparison. Lancet. 2005 Jan 22-28; 365(9456):305-11.
    View in: PubMed
    Score: 0.004
  169. Computer-aided diagnosis scheme for detection of polyps at CT colonography. Radiographics. 2002 Jul-Aug; 22(4):963-79.
    View in: PubMed
    Score: 0.003
  170. Computerized detection of colonic polyps at CT colonography on the basis of volumetric features: pilot study. Radiology. 2002 Feb; 222(2):327-36.
    View in: PubMed
    Score: 0.003
  171. CT colonography with three-dimensional problem solving for detection of colonic polyps. AJR Am J Roentgenol. 1998 Oct; 171(4):989-95.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.